Clinical development of antivirals against SARS-CoV-2 and its variants
Qiaoshuai Lan(Chinese University of Hong Kong), Shibo Jiang(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Yan Yan(Army Medical University), Jie Zhou(Fudan University), Guangxu Zhang(Shanghai Medical College of Fudan University), Lu Lu(Fudan University)
Cited by 9
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
|The Lancet|2017|856
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
|Emerging Microbes & Infections|2021|474
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400